TPK-Targeted Alzheimer's Models for Multi-Pathology Simulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models for Alzheimer's disease primarily based on the Aβ cascade hypothesis fail to simulate the multiple pathophysiological changes in AD brains, and treatments targeting a single mechanism are ineffective in clinical trials, necessitating the development of new therapeutic targets and animal models that can replicate the complex nature of AD.
Innovation Solution
Utilizing TPK gene or protein as a target, promoting its kinase activity and/or expression level to construct an animal model through gene knockout, specifically targeting exon 4 in rodents, and employing vectors like Bacterial Artificial Chromosome and recombinant adeno-associated virus (rAAV) to induce AD-like pathophysiological changes, including glucose metabolism disorders and neurodegeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If animal models are established based on the Aβ cascade hypothesis, then the models can be constructed using existing genetic approaches, but the models fail to simulate the multiple pathophysiological changes in AD brains
Solution Approach 1:
The patent segments the complex AD pathophysiology into multiple independent genetic modifications. Instead of relying on a single Aβ cascade model, the invention creates animal models with combined genetic alterations including APP mutations, BACE1 overexpression, and Tau protein modifications. This segmentation allows each pathophysiological feature to be independently controlled and combined, achieving comprehensive simulation of AD characteristics while maintaining constructability through modular genetic approaches.
2Device complexity
If medicaments target a single mechanism in AD, then the drug development process is simplified, but the treatments are ineffective in clinical trials
Solution Approach 1:
The patent creates animal models with multi-functional genetic modifications that simultaneously exhibit multiple AD pathophysiological features. The models include combined APP mutations with BACE1 overexpression and Tau modifications, allowing them to display Aβ deposition, glucose metabolism disorders, and neurodegeneration concurrently. This multi-functionality in models enables testing of comprehensive therapeutic strategies that address multiple mechanisms simultaneously, bridging the gap between simplified drug designs and complex disease reality.
3Productivity
If existing animal models are used for AD research, then the research can proceed with current methodologies, but the models cannot completely simulate the multiple pathophysiological changes in AD brain
Solution Approach 1:
The patent creates composite animal models by combining multiple genetic modifications within single organisms. The models integrate APP mutations, BACE1 overexpression, and Tau protein alterations to produce a composite phenotype that simultaneously exhibits Aβ deposition, glucose metabolism disorders, and neurodegeneration. This composite approach maintains research productivity by using established genetic engineering methodologies while achieving complete pathophysiological simulation through the synergistic combination of multiple genetic elements.
Data Source
AI summary
Provided is use of thiamine pyrophosphokinase TPK as a target in the treatment of Alzheimer's disease; and AD symptoms due to the inhibited TPK can be prevented by promoting the kinase activity and/or expression level of TPK protein in brain with TPK as a target.